Journal of the American Society of Nephrology
2007 JASN IMPACT FACTOR 7.111 HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP 
    advanced
CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION


Published ahead of print on June 28, 2006
J Am Soc Nephrol 17: 2236-2244, 2006
© 2006 American Society of Nephrology
doi: 10.1681/ASN.2006030196
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
ASN.2006030196v1
17/8/2236    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Di Paolo, S.
Right arrow Articles by Schena, P. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Di Paolo, S.
Right arrow Articles by Schena, P. F.

Clinical Nephrology

Chronic Inhibition of Mammalian Target of Rapamycin Signaling Downregulates Insulin Receptor Substrates 1 and 2 and AKT Activation: A Crossroad between Cancer and Diabetes?

Salvatore Di Paolo, Annalisa Teutonico, Domenica Leogrande, Carmen Capobianco and Paolo F. Schena

Department of Emergency and Organ Transplants, Division of Nephrology, Dialysis and Transplantation, University of Bari, Policlinico, Bari, Italy

Address correspondence to: Dr. Salvatore Di Paolo, Department of Emergency and Organ Transplants, Division of Nephrology, Dialysis and Transplantation–University of Bari, Policlinico-Piazza Giulio Cesare, 11-70124 Bari, Italy. Phone: +39-080-5593231; Fax: +39-080-5593227; E-mail: s.dipaolo{at}nephro.uniba.it

Received for publication March 4, 2006. Accepted for publication May 4, 2006.

Overactivation of the mammalian target of rapamycin (mTOR) branch downstream of the phosphatidylinositol 3-kinase–AKT pathway critically modulates insulin and growth factor signaling by insulin receptor substrates (IRS). On the basis of in vitro studies, the mTOR inhibitor rapamycin has been reported to lead to enhanced activation of AKT by relieving this feedback inhibition on IRS function. In view of the critical role of AKT in insulin signaling and tumorigenesis, the in vivo expression and activation of this kinase and of IRS-1 and IRS-2 were explored in PBMC of 30 patients who were treated long term with rapamycin. A marked decrease of basal and insulin-stimulated AKT phosphorylation, which correlated with the increase of patients’ insulin resistance, and a significant increase of IRS total protein expression, together with a lower (IRS-2) or absent (IRS-1) increase of insulin-induced tyrosine phosphorylation, were found. Therefore, contrary to the expectations, long-term exposure to rapamycin caused the impairment of IRS signaling and AKT activation, and this would help to explain the antiproliferative effect and the possible deterioration of glucose metabolism that are observed in rapamycin-treated patients. These findings may form a novel basis for improved understanding of the role of mTOR inhibition in human diseases, such as diabetes and cancer.




This article has been cited by other articles:


Home page
 NEJMHome page
M. H. Kulke, E. K. Bergsland, and J. C. Yao
Glycemic Control in Patients with Insulinoma Treated with Everolimus
N. Engl. J. Med., January 8, 2009; 360(2): 195 - 197.
[Full Text] [PDF]

Home page
 Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
A. M. Miller, J. R. Brestoff, C. B. Phelps, E. Z. Berk, and T. H. Reynolds IV
Rapamycin does not improve insulin sensitivity despite elevated mammalian target of rapamycin complex 1 activity in muscles of ob/ob mice
Am J Physiol Regulatory Integrative Comp Physiol, November 1, 2008; 295(5): R1431 - R1438.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
O. Johnston, C. L. Rose, A. C. Webster, and J. S. Gill
Sirolimus Is Associated with New-Onset Diabetes in Kidney Transplant Recipients
J. Am. Soc. Nephrol., July 1, 2008; 19(7): 1411 - 1418.
[Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
M. Pavlakis and A. S. Goldfarb-Rumyantzev
Diabetes after Transplantation and Sirolimus: What's the Connection?
J. Am. Soc. Nephrol., July 1, 2008; 19(7): 1255 - 1256.
[Full Text] [PDF]

Home page
 DiabetesHome page
M. Fraenkel, M. Ketzinel-Gilad, Y. Ariav, O. Pappo, M. Karaca, J. Castel, M.-F. Berthault, C. Magnan, E. Cerasi, N. Kaiser, et al.
mTOR Inhibition by Rapamycin Prevents {beta}-Cell Adaptation to Hyperglycemia and Exacerbates the Metabolic State in Type 2 Diabetes
Diabetes, April 1, 2008; 57(4): 945 - 957.
[Abstract] [Full Text] [PDF]

Home page
 J. Appl. Physiol.Home page
R. A. Frost and C. H. Lang
Protein kinase B/Akt: a nexus of growth factor and cytokine signaling in determining muscle mass
J Appl Physiol, July 1, 2007; 103(1): 378 - 387.
[Abstract] [Full Text] [PDF]


HOME CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION AUTHOR INFO
EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP

Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673